Cvrx, Inc.

Health Care
Medical/Dental Instruments
www.cvrx.com

Moat Score
Safety Score

Market Cap $168.34M
PE -3
Debt $50.00M
Cash $105.93M
EV $112.41M
FCF -$40.51M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$59.97M
EBIT	-$59.49M
ROE	-84%
ROA	-45%
FCF	-$40.51M
Equity	$71.06M
Growth Stability	1
PE	-2.81
PB	2.37
P/FCF	-4.16
P/S	3.28
Price/Cash	0.63
Debt/Equity	0.7
Debt/FCF	-1.23
Net Margins	-117%
Gross Margins	84%
Op. Margins	-116%
Sales Growth YoY	36%
Sales Growth QoQ	15%
Sales CAGR	64%
Equity CAGR	-25%
Earnings Growth YoY	16%

Earnings Growth QoQ	-19%
Sales CAGR 5Y	64%
Equity CAGR 5Y	-25%
Earnings CAGR 3Y	61%
Sales CAGR 3Y	61%
Equity CAGR 3Y	-26%
Market Cap	$168.34M
Revenue	$51.29M
Assets	$133.41M
Total Debt	$50.00M
Cash	$105.93M
Shares Outstanding	22.6M
EV	112.41M
Moat Score	1%
Safety Score	64%
Working Capital	119.05M
Current Ratio	12.06
Gross Profit	$42.96M
Shares Growth 3y	3%
Equity Growth QoQ	9%
Equity Growth YoY	-6%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.

SEC Filings

Direct access to Cvrx, Inc. (CVRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cvrx, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cvrx, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Cvrx, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cvrx, Inc..

Years

Calculation mode

= -$405M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$41M	-$405M
DCF		-$37M	-$33M	-$30M	-$28M	-$25M	-$23M	-$21M	-$19M	-$17M	-$16M	-$156M
Value	-$405M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-237%	-330%	-184%	-105%	-117%	-117%
ROA	-	-17%	-33%	-36%	-45%	-45%
ROE	-	-30%	-38%	-54%	-84%	-84%

Bad Net Margins (-116.91%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-0	-0.16	-0.76	-1.23	-1.23
Debt over Equity	-0.07	0	0.06	0.4	0.7	0.7
Growth Stability	-	-	-	-	-	1

Good Debt/FCF ratio (-1.23)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.7)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	115%	72%	75%	31%	64%
Earnings YoY growth	-	201%	-4%	-1%	46%	-
Equity YoY growth	-	-150%	-25%	-30%	-6%	-25%
FCF YoY growth	-	76%	50%	-9%	2%	-